While the disease can take many forms, recent advances have better characterized
how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches.
Not exact matches
«Ultimately, we needed 20 years to learn
how to supercharge these
cells to deliver anticancer activity,» says Arie Belldegrun, president and CEO of Kite Pharma in Santa Monica, California, which is assessing CAR T
cells in six trials for B
cell leukemia and
lymphomas, and glioblastoma.
In the journal
Cell Reports, published today online, the scientists describe
how the powerful master regulatory transcription factor Bcl6 regulates the genome, ensuring that aggressive
lymphomas survive and thrive.
We believe that each dog breed may correspond to one type of B - or T -
cell lymphoma and so studies within and between breeds gives us a unique possibility to understand
how the genetic background affects what type of tumor develops, and
how its progression is regulated,» says Ingegerd Elvers.
But little is known about
how B
cell metabolism adapts to each of these environments, insights that may improve our understanding of B
cell diseases, such as non-Hodgkin's
lymphoma.
We believe that each dog breed may correspond to one type of B - or T -
cell lymphoma and so studies within and between breeds gives us a unique possibility to understand
how the genetic background affects what type of tumour develops, and
how its progression is regulated», says Ingegerd Elvers.
«Right now we don't know
how TET mutations specifically contribute to either T
cell lymphomas or leukemias.
This determination is based on
how rapidly the cancer
cells appear to be dividing and
how malignant the
cells appear to be; high - grade
lymphoma is fast - growing and more malignant.
Lectures provided on: Canine and Feline
Lymphoma, What's new in Oncology,
How to read a histopathology report; Canine mast
cell tumours and TKIs; Canine Hemangiosarcoma.